Accès gratuit
Numéro
Med Sci (Paris)
Volume 22, Numéro 2, Février 2006
Page(s) 183 - 187
Section M/S revues
DOI https://doi.org/10.1051/medsci/2006222183
Publié en ligne 15 février 2006
  1. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alpha-2b adjuvant therapy of high-risk resected cutaneous melanoma : the Eastern cooperative oncology group trial EST 1684. J Clin Oncol 1996; 14 : 7–17. [Google Scholar]
  2. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004; 351 : 998–1012. [Google Scholar]
  3. Clark WH Jr, Elder DE, Guerry D 4th, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst1989; 81 : 1893–904. [Google Scholar]
  4. Rosenberg SA, Lotze MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985; 313 : 1485–92. [Google Scholar]
  5. Rosenberg SA, Dudley ME. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci USA 2004; 101 : 14639–45. [Google Scholar]
  6. Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 2003; 3 : 666–75. [Google Scholar]
  7. Yee C, Thompson JA, Byrd D, et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma : in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 2002; 99 : 16168–73. [Google Scholar]
  8. Labarriere N, Pandolfino MC, Gervois N, et al. Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients. Cancer Immunol Immunother 2002; 51 : 532–8. [Google Scholar]
  9. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298 : 850–4. [Google Scholar]
  10. Berd D. M-Vax : an autologous, hapten-modified vaccine for human cancer. Exp Opin Ther 2002; 2 : 335–42. [Google Scholar]
  11. Mitchell MS, Rechtman DJ, Von Eschen KB. A randomized phase III trial of Melacine versus combination chemotherapy in patients with disseminated melanoma. Can J Infect Dis 1995; 6 (suppl C) : 347. [Google Scholar]
  12. Hsueh E, Gupta R, Qi K, Morton D. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine. J Clin Oncol 1998; 16 : 2913–20. [Google Scholar]
  13. Hsueh EC, Essner R, Foshag LJ, et al. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol 2002; 20 : 4549–54. [Google Scholar]
  14. Parmiani G, Rodolfo M, Melani C. Immunological gene therapy with ex vivo gene-modified tumor cells : a critique and a reappraisal. Hum Gene Ther 2000; 11 : 1269–75. [Google Scholar]
  15. Soiffer R, Hodi FS, Haluska F, et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol 2003; 21 : 3343–50. [Google Scholar]
  16. C Castelli, L Rivoltini, F Rini. Heat shock proteins : biological functions and clinical application as personalized vaccines for human cancer. Cancer Immunol Immunother 2004 : 53 : 227–233. [Google Scholar]
  17. Belli F, Testori A, Rivoltini L, et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes : clinical and immunologic findings. J Clin Oncol 2002; 20 : 4169–80. [Google Scholar]
  18. Parmiani G, Castelli C, Dalerba P, et al. Cancer immunotherapy with peptide-based vaccines : what have we achieved ? Where are we going ? J Natl Cancer Inst 2002; 94 : 805–18. [Google Scholar]
  19. Daniel E, Speiser A, Mikaël J, et al. Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells. Semin Cancer Biol 2003; 13 : 461–72. [Google Scholar]
  20. Lonchay C, van der Bruggen P, Connerotte T, et al. Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc Natl Acad Sci USA 2004; 101 (suppl : 14631-8). [Google Scholar]
  21. Sanderson K, Scotland R, Lee P et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 2005; 23 : 741–50. [Google Scholar]
  22. Davis ID, Chen W, Jackson H, et al. Recombinant NY-ESO-1 protein with Iscomatrix adjuvant induces broad integrated antibody and CD4 and CD8 T cell responses in humans. Proc Natl Acad Sci USA 2004; 101 : 10697–702. [Google Scholar]
  23. Thurner B, Haendler I, Roder C, et al. Vaccination with MAGE-3A1 peptide-pulsed mature monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stages IV melanoma. J Exp Med 1999; 190 : 1669–78. [Google Scholar]
  24. Chang AE, Redman BG, Whitfield JR, et al. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin Cancer Res 2002; 8 : 1021–32. [Google Scholar]
  25. Shortman K, Liu YJ. Mouse and human dendritic cell subtypes. Nat Rev Immunol 2002; 2 : 151–61. [Google Scholar]
  26. Wolfers J, Lozier A, Raposo G, et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med 2001; 7 : 297–303. [Google Scholar]
  27. Banchereau J, Palucka AK, Dhodapkar M, et al. Immune and clinical responses in patients with metastatic melanoma to CD34+ progenitor-derived dendritic cell vaccine. Cancer Res 2001; 61 : 6451–8 [Google Scholar]
  28. Paczesny S, Ueno H, Fay J, et al. Dendritic cells as vectors for immunotherapy of cancer. Semin Cancer Biol 2003; 13 : 439–47. [Google Scholar]
  29. Escudier B, Dorval T, Chaput N, et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes : results of the first phase I clinical trial. J Transl Med2005; 3 : 10. [Google Scholar]
  30. Ghiringhelli F, Larmonier N, Schmitt E, et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004; 34 : 336–44. [Google Scholar]
  31. Germeau C, Ma W, Schiavetti F, et al. High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J Exp Med 2005; 201 : 241–8. [Google Scholar]
  32. Movassagh M, Spatz A, Davoust J, et al. Selective accumulation of mature DC-Lamp+ dendritic cells in tumor sites is associated with efficient T-cell-mediated antitumor response and control of metastatic dissemination in melanoma. Cancer Res 2004; 64 : 2192–8. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.